Sodium Channel Mutations in Patient With the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)

Chronic Pain Syndrome Clinical Trial

— Nav-ACNES  

Official title:

Sodium Channel Mutations (SCN9A, SCN10A) in the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05877274
• Other study ID #: NL84021.015.23
• Status: Recruiting
• Start date: October 3, 2023
• Est. completion date: December 2024

Study information

• Verified date: May 2023
• Source: Maxima Medical Center
• Contact: Tom ten Have, MD
• Phone: 0408887461
• Email: Tom.ten.Have[@]mmc.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to learn about sodium channel (Nav) mutations in patients with the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES). This study will give more insight into the pathophysiology of ACNES, which is still largely unknown. The primary objective is to determine if there are mutations of Nav1.7 and Nav1.8 in patients with ACNES. Therefore, one blood sample will be drawn, in which the mutations will be analyzed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

In order to be eligible to participate in this study, a subject must be diagnosed with ACNES and receive treatment at our outpatient clinic. Additionally, subject has to meet one

of the following criteria:

• Known to have a first- or second-degree relative with ACNES;
• Have more than one recurrence of ACNES after a pain free period or ACNES at multiple locations in the abdominal wall;
• Persistent pain after posterior neurectomy.

Exclusion Criteria:

• Inability to understand Dutch language.
• Known neuromuscular or neurodegenerative disease.

Related Conditions & MeSH terms

• Charcot-Marie-Tooth Disease
• Chronic Pain
• Chronic Pain Syndrome
• Hereditary Sensory and Motor Neuropathy
• Nerve Compression Syndromes
• Nerve Entrapment Syndrome
• Syndrome

Intervention

Other:
• Sodium channel mutation
Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.

Locations

Country	Name	City	State
Netherlands	Maxima Medical Center	Veldhoven

Sponsors (1)

Lead Sponsor	Collaborator
Maxima Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sodium Channel 1.7 and 1.8 mutation.	Number of SCN9A and SCN10A mutations. Each mutation will be classified following one of three classes; unknown pathogenicity, probable pathogenicity, and pathogen variant.	Blood samples for SCN analysis will be taken only once after obtaining informed consent. This is the start of the study. Outpatient discharge (free of pain or no treatment options) is end of study. Treatment period can be a couple of weeks or months.
Secondary	Correlation between mutations and known cause of ACNES.	Patients are asked (standard of care) if there is a possible cause of the ACNES. Correlations between the causes of ACNES and any identified mutations will be examined.	Baseline data will be obtained during first outpatient visit, before start of the treatment. The first outpatient visit takes 30 minutes (standard of care).
Secondary	Correlation between mutations and pain score at start of treatment.	Patients are asked (standard of care) about the average pain score following the 0-10 numeric rating scale (NRS) (0 = no pain, 10 worst possible pain).; Correlations between the NRS pain score and found mutations will be examined.	Baseline data will be obtained during first outpatient visit, before start of the treatment. The first outpatient visit takes 30 minutes (standard of care).
Secondary	Correlation between mutations and treatment response.	Patients follow different treatments according standard of care for ACNES. Starting with trigger point injections with a local anesthetic, if this treatment is not sufficient, it is followed by Pulse Radiofrequency. When patients still experience pain after minimal invasive treatments, a surgical neurectomy is performed.; Correlations between treatment outcome after the different treatment options and found mutations will be examined. Treatment is defined successful if the patient does not need additional treatment, has >50% pain reduction, or reduction of >4 NRS points.	Treatment response will be assessed after each treatment during the treatment period at our outpatient clinic, up to 6 weeks after treatment.